Know What's Happening in BioTech
Know What's Happening in BioTech
BioTech Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Brazilian researchers have shown that an iron‑based compound, ferroin, encapsulated in lipid nanoparticles, completely eradicated Mycobacterium tuberculosis from mouse lungs after a 30‑day course. The formulation, LNP@FEP, stabilizes the drug, enhances the activity of existing antibiotics, and targets bacterial cell‑wall synthesis. Current TB therapy requires six months of multidrug regimens, with resistance driving longer, more toxic treatments. Because ferroin is inexpensive and unpatented, it could enable low‑cost, shorter regimens pending human trials.
2026’s leading women CEOs in pharma and biotech are steering some of the industry’s biggest strategic moves, from multi‑billion‑dollar investments to landmark FDA approvals. The list includes Julie Kim’s upcoming Takeda leadership, Emma Walmsley’s transition at GSK, Reshma Kewalramani’s growth...
The FDA has removed several accelerated approvals for non‑malignant hematological, neurological, and other disorder indications after post‑marketing requirements were withdrawn. These withdrawn indications are not reflected in official listings until a Federal Register notice or label update is issued. The...
Dotinurad (FYU‑981), marketed as Urece®, is a URAT1 inhibitor approved for gout and hyperuricemia in Japan and China. The drug was chemically refined from the older uricosuric benzbromarone to retain potency while eliminating rare hepatotoxic events. Crystalys Therapeutics is now...
The FDA’s ongoing accelerated‑approval list details 30+ drugs for non‑malignant hematologic, neurologic and other rare disorders that remain contingent on post‑marketing requirements (PMRs). Each entry cites the indication, approval date, specific confirmatory trial design, and a projected completion date ranging...
The FDA’s Accelerated Approval Program permits earlier market entry for drugs treating serious conditions by relying on surrogate endpoints that predict clinical benefit. Companies must later complete confirmatory trials; positive results convert the approval to traditional status, while negative outcomes...
Apheris has launched the ADMET Network, a federated learning platform that lets pharmaceutical companies jointly train ADMET prediction models without exposing raw data. Five founding members—Lundbeck, Orion Pharma, Recursion, Servier and an undisclosed partner—have each contributed roughly 80% of their...
Psychedelic tape still trades on vibes > policy. Surgeon General nominee Casey Means says she “would not recommend” psilocybin to the American people today. Yes, she nods to “exciting work” in PTSD and veterans. But that is a far cry from...
Stem cell therapies for neurodegenerative diseases span unregulated, low‑evidence clinics to proprietary, patent‑protected programs seeking regulatory approval. A new narrative review compiles trial outcomes, highlighting modest benefits—primarily brief inflammation reduction—and significant variability across patients and cell batches. The paper also...
An experimental cell therapy for a rare post‑transplant blood cancer, developed by Atara Biotherapeutics and Pierre Fabre, was initially deemed approvable by FDA reviewers but was abruptly rejected in February 2026 over alleged clinical data deficiencies. The disease affects roughly...
The FDA has approved Braftovi for patients with BRAF V600E‑mutant metastatic colorectal cancer, expanding targeted options in a genetically defined subset. The clearance underscores the momentum of biomarker‑driven oncology and combination‑therapy strategies. In parallel, Novo Nordisk announced a $2 billion partnership with Vivtex...
One company is unlocking gene delivery to overcome the challenges that held back the promise of genetic medicine. If you want to learn more, they’ll be hosting an exclusive fireside chat at 9am Thursday, May 7th at SynBioBeta. Last year at...
An experimental therapy for a rare blood cancer was on the path toward approval by the Food and Drug Administration last year — with internal reviewers recommending it be cleared — before the agency rejected the drug last month, @adamfeuerstein...
Muvon Therapeutics, a clinical‑stage company developing regenerative muscle treatments, is confronting the translation gap between academic discovery and commercial manufacturing. The firm highlights three core hurdles: co‑developing evolving regulatory frameworks, automating novel manufacturing processes, and recruiting personnel with GMP expertise....
Interesting read: the thread and the story. A drug that was approved in Europe in 2022, which looked like it was on track for #FDA approval, instead is rejected. What changed at FDA? 🤔
The Federal Register notice for the (now) March #ACIP meeting is now up & it's ... puzzling. Possible vote on Covid vaccine injury? ACIP can recommend changes to the way a vaccine is used, for safety reasons. But vaccine injuries aren't...
Artificial intelligence is transitioning from offline analysis to active laboratory roles, yet bioprocess engineering faces unique biological and regulatory hurdles. A recent review advocates hybrid laboratories that blend AI‑driven automation for core tasks with human oversight for auxiliary processes. High‑throughput...
$LTRN is a live experiment in our thesis: AI doesn’t need to invent new drugs. It needs to improve probability of success in humans. If RADR consistently enriches responders, that’s durable value. If not, platform premium disappears. Listen to the podcast here: https://t.co/ZAg5btpcIK
interesting and different efficacy outcomes in ASyS and SSc autoimmune patients treated with blinatumomab (CD3/CD19) and teclistamab (CD3/BCMA), respectively, + Rituximab maintenance. Potential for targeting both BCMA and CD19, especially in ASys. https://t.co/Dyq7h9EeGo
Samsung Biologics has joined the Coalition for Epidemic Preparedness Innovations (CEPI) Vaccine Manufacturing Facility Network, committing to develop a ready‑to‑activate recombinant protein vaccine platform. Backed by a $20 million budget, Samsung will pre‑agree manufacturing processes, run simulated outbreak drills, and prepare...
Researchers at Iowa State University have unveiled a Taylor Vortex Fermenter‑Extractor‑Separator that combines fermentation, extraction and separation in a single unit. The concentric‑cylinder design creates Taylor vortices, delivering uniform mixing while minimizing cell damage. Higher mass‑transfer rates cut gas consumption,...
Richard Pops will step down as Alkermes CEO on July 31 after a 32‑year tenure, remaining as board chair. COO Blair Jackson will succeed him and join the board during the transition. Under Pops, Alkermes shifted from drug‑delivery to commercial...
Quorix, a new private research platform, concentrates on the convergence of decentralized finance, artificial intelligence, biotechnology, and physical intelligence. It delivers structured, forward‑looking analysis for venture capital funds, family offices, angel investors, and tech founders seeking cross‑sector insights. By mapping...
Music Beats Cancer, a nonprofit founded by former cancer researcher Mona Jhaveri, uses live music and a peer‑to‑peer platform to funnel public donations directly to early‑stage biotech firms tackling cancer. By turning song likes into dollars, the organization bridges the...
Researchers at Tokyo University of Science have created a water‑based enzyme ink that allows screen‑printing of both anode and cathode layers of enzymatic biofuel cells in a single step. The printed lactate/oxygen biofuel cell delivered a peak power density of...
A randomized trial of a stem cell therapy vs placebo for aging frailty showed durable and dose-dependent improvement in the 6-minute walk test @CellStemCell https://t.co/2jOYuIgUrY https://t.co/04mEV7OdLo
Identification of Significant Barriers to Accrual (BtA) to @theNCI Sponsored Multiple Myeloma – Clinical Trials (MM-CT): A Step towards Improving Accrual to #ClinicalTrials - @mweissmdphd et al. #ASH12 Abstract 3165 https://t.co/i4zO7ktqHJ #mmsm #caxtx #ctsm
A recent analysis of the REPRIEVE randomized trial shows that pitavastatin reduces incident hypertension by 17 % and cuts major adverse cardiovascular events (MACE) by 36 % in adults living with HIV. The findings extend statins’ benefit beyond LDL‑cholesterol lowering, highlighting a...
#EAOnc EQUATE EAA181 Effective Quadruplet Utilization After Tx Evaluation: Ph3 RCT NDMM Not Intended for Early ASCT [Activated: 10/27/20] PI= @myelomaMD https://t.co/qD26HMx3J8 #NCT04566328 #mmMRD #mmsm @eaonc @mweissmdphd @VincentRK @LynneWagnerPhD Wei Snyder Kostakoglu @mtmdphd
.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] https://t.co/OizUfJCc2c #mmsm #bmtsm https://t.co/uikUnnJd3n
NASA’s BioNutrients-3 experiment aboard the International Space Station uses engineered probiotic cultures to ferment nutrient‑dense foods on demand, addressing the shelf‑life limits of essential vitamins for long‑duration missions. Astronaut Kimiya Yui demonstrated production bags containing yogurt cultures, and the samples...
New @Nature The brains of Super Agers produce more neurons than people some 40 years younger, a neurogenesis resilient signature linked to exceptional cognitive health and memory skills https://t.co/tNB0dTea2F
Researchers at Nagoya University have unveiled an iron‑based photocatalyst that matches or exceeds the performance of traditional ruthenium and iridium systems while dramatically lowering material costs. The new catalyst combines inexpensive achiral bidentate ligands with a reduced amount of tailored...
Researchers have uncovered that formate, a by‑product of photorespiration, serves as a direct donor for one‑carbon units used in DNA methylation in plants. The study demonstrates a mechanistic link between metabolic flux in the chloroplast and epigenetic modifications in the...
The FDA has cleared Cepheid’s Xpert GI Panel, a multiplex PCR test that identifies 11 gastrointestinal pathogens—including eight bacteria, two parasites and one virus—from a single stool sample. Results are available in just over an hour, dramatically faster than traditional culture...
Comparative Effectiveness and Safety of PI-Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT-MM Data Analysis [Jan 13, 2026] @NoemiPuigM et al. European Journal of Haematology https://t.co/Vf7USecLlR #NCT02761187 #mmsm #openaccess https://t.co/C5Ya6TTQfo
Assessment of biological age integrating electronic medical records and multi-omics increases accuracy for predicting outcomes @NatureAging https://t.co/7y60SSPTQf https://t.co/u02OlWMdQz
The FDA’s Center for Drug Evaluation and Research has launched the Learning and Education to ADvance and Empower Rare Disease Drug Developers (LEADER 3D) initiative under its Accelerating Rare disease Cures (ARC) program. LEADER 3D provides a suite of educational videos, downloadable...
Gibson Oncology has launched a Phase 2 trial of its dual‑action drug LMP744 in patients with first‑time recurrent glioblastoma. The compound simultaneously inhibits topoisomerase 1 and down‑regulates the cMYC oncogene, aiming to disrupt tumor proliferation. The study will enroll about 40 patients,...
Researchers evaluated crude extracts from the African weed Tithonia diversifolia and the nightshade Solanum torvum for antibacterial activity against several Shigella strains. In vitro assays demonstrated clear zones of inhibition, with minimum inhibitory concentrations between 125 µg/mL and 250 µg/mL. Both extracts...
The study introduces BG/SOD@ZIF‑zc, a multifunctional nanoplatform that encapsulates superoxide dismutase within a copper‑doped ZIF framework and coats it with bacterial ghosts for targeted delivery to the colon. The formulation retains SOD activity in the harsh gastrointestinal tract, efficiently scavenges...
What gets missed in the hurly burly of a conference with many highlight reels? Here we explore emerging trends to watch out for when it comes to protein degradation/glues, & combination opportunities w/ CAR-T cells. Time for some...
1/ If you're doing bioinformatics without Git, you're gambling with your research. Here are 6 Git commands every bioinformatician must know 🧵 https://t.co/gFhsTYIsMv
The article argues that the next wave of hematologic‑malignancy therapies will be shaped by early‑stage signals emerging from conference hallways rather than headline‑grabbing late‑phase trial data. It identifies five nascent trends—advanced immunotherapies, precision genomics, micro‑environment targeting, novel biomarker platforms, and...
The FT's report on GSK's $950M deal to buy 35Pharma and its pulmonary arterial hypertension drug includes an interesting unnamed insider's quote that new CEO Luke Miels is going after assets where "the science is relatively settled." Maybe leaning into...
Verdiva Bio announced that enrollment for its phase 2b EVOLVE‑2 trial of VRB‑101, a once‑weekly oral GLP‑1 peptide analog for weight loss, is complete with more than 200 participants across 22 U.S. sites. The double‑blind, placebo‑controlled study will assess safety, tolerability...
Strong claim that needs independent replication: "Our findings provide compelling evidence that circulating smRNAs—especially piRNAs—are powerful predictors of survival in older adults and potential biomarkers of longevity" https://t.co/oi4220zxGY https://t.co/yk3MX4VdQj
Infertility has long been framed as a women's issue, yet about half of cases stem from male factors. New treatments such as Igyxos' IGX12 monoclonal antibody, which enhances follicle‑stimulating hormone activity, aim to improve sperm production and reduce the physical...
Illumina has rebranded its Constellation mapped‑read system as TruePath Genome and launched it commercially at $395 per genome. The technology performs on‑flowcell tagmentation of high‑molecular‑weight DNA, using DRAGEN to infer proximity and generate haplotype blocks on NovaSeq X 10B flowcells. TruePath Genome claims...
